UA114896C2 - Цитомегаловірус, який умовно реплікується, як вакцина проти cmv - Google Patents
Цитомегаловірус, який умовно реплікується, як вакцина проти cmvInfo
- Publication number
- UA114896C2 UA114896C2 UAA201403638A UAA201403638A UA114896C2 UA 114896 C2 UA114896 C2 UA 114896C2 UA A201403638 A UAA201403638 A UA A201403638A UA A201403638 A UAA201403638 A UA A201403638A UA 114896 C2 UA114896 C2 UA 114896C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cmv
- present
- infection
- replication
- vaccine
- Prior art date
Links
- 241000701022 Cytomegalovirus Species 0.000 title abstract 8
- 230000003362 replicative effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 230000010076 replication Effects 0.000 abstract 3
- 230000002950 deficient Effects 0.000 abstract 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract 1
- 206010042566 Superinfection Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007420 reactivation Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Винахід стосується умовно-дефектного по реплікації цитомегаловірусу (CMV), який містить пентамерний gH-комплекс, який включає в себе UL128, UL130, UL131, gH і gL та нуклеїнову кислоту, що кодує перший злитий білок між ІЕ1/2 і дестабілізуючим білком та другий злитий білок між UL51 і дестабілізуючим білком, причому дестабілізуючий білок є похідним FK506-зв’язувального білка (FKBP), що має амінокислотні заміни F36V і L106P, де дикий тип IE1/2 і UL51 більше не присутній та де CMV є атенуйованим штамом, який відновлює складну експресію gH завдяки репарації мутації в гені UL131.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161532667P | 2011-09-09 | 2011-09-09 | |
PCT/US2012/053599 WO2013036465A2 (en) | 2011-09-09 | 2012-09-04 | A conditional replicating cytomegalovirus as a vaccine for cmv |
Publications (1)
Publication Number | Publication Date |
---|---|
UA114896C2 true UA114896C2 (uk) | 2017-08-28 |
Family
ID=47832753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201403638A UA114896C2 (uk) | 2011-09-09 | 2012-09-04 | Цитомегаловірус, який умовно реплікується, як вакцина проти cmv |
Country Status (33)
Country | Link |
---|---|
US (1) | US9546355B2 (uk) |
EP (3) | EP3572096A1 (uk) |
JP (1) | JP5926804B2 (uk) |
KR (1) | KR101668163B1 (uk) |
CN (1) | CN103889462B (uk) |
AR (1) | AR087772A1 (uk) |
AU (1) | AU2012304783B2 (uk) |
BR (1) | BR112014005404A8 (uk) |
CA (1) | CA2846870C (uk) |
CL (1) | CL2014000541A1 (uk) |
CY (2) | CY1119107T1 (uk) |
DK (2) | DK3251700T3 (uk) |
ES (2) | ES2737852T3 (uk) |
HR (2) | HRP20171120T1 (uk) |
HU (2) | HUE045115T2 (uk) |
IL (1) | IL231272B (uk) |
IN (1) | IN2014CN01809A (uk) |
LT (2) | LT3251700T (uk) |
ME (2) | ME03488B (uk) |
MX (1) | MX353037B (uk) |
NZ (1) | NZ622156A (uk) |
PE (1) | PE20141525A1 (uk) |
PL (2) | PL3251700T3 (uk) |
PT (2) | PT3251700T (uk) |
RS (2) | RS58891B1 (uk) |
RU (2) | RU2611198C2 (uk) |
SG (1) | SG11201400419YA (uk) |
SI (2) | SI2753364T1 (uk) |
TR (1) | TR201910644T4 (uk) |
TW (1) | TWI570240B (uk) |
UA (1) | UA114896C2 (uk) |
WO (1) | WO2013036465A2 (uk) |
ZA (1) | ZA201401708B (uk) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013355368A1 (en) * | 2012-12-04 | 2015-05-28 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
BR112015030892A2 (pt) * | 2013-06-10 | 2017-08-29 | Merck Sharp & Dohme | Proteína de ligação ao antígeno, anticorpo monoclonal, ácido nucleico recombinante, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma proteína de ligação ao antígeno ou anticorpo humanizado, e, método para produzir uma proteína de ligação ao antígeno |
EP3169787A1 (en) | 2014-07-16 | 2017-05-24 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
KR20200083540A (ko) * | 2017-11-01 | 2020-07-08 | 머크 샤프 앤드 돔 코포레이션 | 시토메갈로바이러스의 안정한 제형 |
EP3784276A4 (en) * | 2018-04-24 | 2022-03-16 | Merck Sharp & Dohme Corp. | SCALABLE CHROMATOGRAPHY METHOD FOR THE PURIFICATION OF HUMAN CYTOMEGALOVIRUS |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
WO2020142304A1 (en) | 2019-01-03 | 2020-07-09 | Merck Sharp & Dohme Corp. | Supplemented serum-containing culture medium for enhanced arpe-19 growth and human cytomegalovirus vaccine production |
WO2021008840A1 (en) * | 2019-07-12 | 2021-01-21 | Københavns Universitet | Fusion toxin proteins for treatment of diseases related to cmv infections |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN112481222B (zh) * | 2020-11-30 | 2024-01-02 | 中国医学科学院医学生物学研究所 | 一种条件复制型重组单纯疱疹病毒、疫苗及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1150712T1 (sl) * | 1999-02-05 | 2009-02-28 | Merck & Co Inc | Pripravek cepiva proti humanem papiloma virusu |
CA2756797C (en) | 2002-12-23 | 2015-05-05 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US20060110406A1 (en) * | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
WO2004076645A2 (en) * | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions and methods for cytomegalovirus treatment |
CN101203529A (zh) * | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸 |
EP3031469B1 (en) * | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
US8530636B2 (en) * | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
-
2012
- 2012-09-03 TW TW101132064A patent/TWI570240B/zh active
- 2012-09-04 SI SI201231003T patent/SI2753364T1/sl unknown
- 2012-09-04 TR TR2019/10644T patent/TR201910644T4/tr unknown
- 2012-09-04 RS RS20190753A patent/RS58891B1/sr unknown
- 2012-09-04 DK DK17171651.7T patent/DK3251700T3/da active
- 2012-09-04 CN CN201280053360.7A patent/CN103889462B/zh active Active
- 2012-09-04 KR KR1020147008959A patent/KR101668163B1/ko active IP Right Grant
- 2012-09-04 JP JP2014529788A patent/JP5926804B2/ja active Active
- 2012-09-04 RS RS20170715A patent/RS56261B1/sr unknown
- 2012-09-04 ES ES17171651T patent/ES2737852T3/es active Active
- 2012-09-04 NZ NZ622156A patent/NZ622156A/en unknown
- 2012-09-04 ME MEP-2019-176A patent/ME03488B/me unknown
- 2012-09-04 HU HUE17171651A patent/HUE045115T2/hu unknown
- 2012-09-04 AR ARP120103253A patent/AR087772A1/es active IP Right Grant
- 2012-09-04 PT PT17171651T patent/PT3251700T/pt unknown
- 2012-09-04 LT LTEP17171651.7T patent/LT3251700T/lt unknown
- 2012-09-04 EP EP19175776.4A patent/EP3572096A1/en active Pending
- 2012-09-04 UA UAA201403638A patent/UA114896C2/uk unknown
- 2012-09-04 MX MX2014002815A patent/MX353037B/es active IP Right Grant
- 2012-09-04 AU AU2012304783A patent/AU2012304783B2/en active Active
- 2012-09-04 ME MEP-2017-157A patent/ME02831B/me unknown
- 2012-09-04 WO PCT/US2012/053599 patent/WO2013036465A2/en active Application Filing
- 2012-09-04 US US14/343,637 patent/US9546355B2/en active Active
- 2012-09-04 BR BR112014005404A patent/BR112014005404A8/pt not_active Application Discontinuation
- 2012-09-04 EP EP17171651.7A patent/EP3251700B1/en active Active
- 2012-09-04 CA CA2846870A patent/CA2846870C/en active Active
- 2012-09-04 DK DK12830346.8T patent/DK2753364T3/en active
- 2012-09-04 PT PT128303468T patent/PT2753364T/pt unknown
- 2012-09-04 SG SG11201400419YA patent/SG11201400419YA/en unknown
- 2012-09-04 IN IN1809CHN2014 patent/IN2014CN01809A/en unknown
- 2012-09-04 RU RU2014113921A patent/RU2611198C2/ru active
- 2012-09-04 PE PE2014000323A patent/PE20141525A1/es active IP Right Grant
- 2012-09-04 PL PL17171651T patent/PL3251700T3/pl unknown
- 2012-09-04 PL PL12830346T patent/PL2753364T3/pl unknown
- 2012-09-04 SI SI201231634T patent/SI3251700T1/sl unknown
- 2012-09-04 ES ES12830346.8T patent/ES2633190T3/es active Active
- 2012-09-04 RU RU2017102888A patent/RU2670012C1/ru active
- 2012-09-04 HU HUE12830346A patent/HUE035322T2/en unknown
- 2012-09-04 LT LTEP12830346.8T patent/LT2753364T/lt unknown
- 2012-09-04 EP EP12830346.8A patent/EP2753364B1/en active Active
-
2014
- 2014-03-02 IL IL231272A patent/IL231272B/en active IP Right Grant
- 2014-03-06 CL CL2014000541A patent/CL2014000541A1/es unknown
- 2014-03-07 ZA ZA2014/01708A patent/ZA201401708B/en unknown
-
2017
- 2017-07-20 HR HRP20171120TT patent/HRP20171120T1/hr unknown
- 2017-07-20 CY CY20171100780T patent/CY1119107T1/el unknown
-
2019
- 2019-06-18 HR HRP20191111TT patent/HRP20191111T1/hr unknown
- 2019-08-06 CY CY20191100836T patent/CY1121863T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA114896C2 (uk) | Цитомегаловірус, який умовно реплікується, як вакцина проти cmv | |
MX2018008413A (es) | Virus oncolitico modificado. | |
PH12017500727A1 (en) | Modified virus-like particles of cmv | |
MA39717A (fr) | Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs | |
PH12015501378A1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
PH12017500419B1 (en) | Recoded arbovirus and vaccines | |
PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. | |
SG11202104486VA (en) | Virus-like particles of cmv modified by fusion | |
CA3045626A1 (en) | Bovine herpesvirus type 1 (bohv-1) vector against bovine respiratory disease complex | |
MX2017014666A (es) | Metodos de inmunización contra clostridium difficile. | |
ECSP14013300A (es) | Un citomegalovirus de replicacion condicionada como vacuna contra el cmv | |
EP3200821A4 (en) | Therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2) | |
MX337048B (es) | Vacuna marcadora para la fiebre porcina clasica. | |
WO2011130652A3 (en) | Compositions and methods for vaccinating humans and animals against enveloped viruses | |
WO2017011620A9 (en) | Methods and compositions related to increasing the fidelity of influenza a virus for vaccine development | |
EP3244922A4 (en) | Methods of inducing an immune response to hepatitis c virus | |
MX2020013284A (es) | Vacuna basada en particulas virales. | |
MX2021015236A (es) | Métodos para el tratamiento contra infecciones virales. | |
GB201803787D0 (en) | Oncolytic viruses as adjuvants | |
AU2015904101A0 (en) | Genetically stable oncolytic virus | |
MY185444A (en) | Enterovirus 71 antiviral peptides | |
MX337551B (es) | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica. |